New-generation therapy for ANCA-associated vasculitis

Clinical and Experimental Nephrology

Volumn 17, Issue 5, 2013, Pages 694-696

  Jayne, David ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

ANCA; Clinical trial; Rituximab; Therapy; Vasculitis

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; BORTEZOMIB; CCX 168; COMPLEMENT COMPONENT C5A; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 5; MEPOLIZUMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; CANCER RISK; CARDIOVASCULAR RISK; CELL THERAPY; CHURG STRAUSS SYNDROME; COMPLEMENT INHIBITION; DISABILITY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENZYME INHIBITION; HUMAN; IMMUNE COMPLEX NEPHRITIS; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PLASMA CELL; PLASMAPHERESIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RELAPSE; REMISSION; REVIEW; SURVIVAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84887227878     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0855-z     Document Type: Review

References (20)

1. Suppiah R, Flossman O, Mukhtyar C, et al. Measurement of damage in systemic vasculitis: a comparison of the vasculitis damage index with the combined damage assessment index. Ann Rheum Dis. 2010;70:80-5.
2. Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63:588-96.
3. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol. 2001;13:48-55.
4. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44.
5. Walsh M, Catapano F, Szpirt W, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis. 2010;57:557-64.
6. Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211-20.
7. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-32.
8. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60:2156-68.
9. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum. 2012;64:3760-9.
10. Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71:327-33.
11. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis. 2008;67:1322-7.
12. Langford CA. L41. Perspectives on the treatment of giant cell arteritis. Presse Med. 2013;42:609-12.
13. Flossmann O, Baslund B, Bruchfeld A, et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis. 2009;68:1125-30.
14. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352:351-61.
15. Laurino S, Chaudhry A, Booth A, et al. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transpl. 2010;25:3307-14.
16. Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57:686-93.
17. Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336-43.
18. Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155:341-3.
19. Bontscho J, Schreiber A, Manz RA, et al. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol. 2011;22:336-48.
20. Kim MJ, McDaid JP, McAdoo SP, et al. Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. J Immunol. 2012;189:3751-8.